Diversity in clinical trials is more than just a box to check off in relation to an organization’s diversity, equity, and inclusion (DEI) practices. Minorities should be included in studies because their symptoms, reactions to medications, and even physiology are different. One-fifth of new drugs approved between 2008 and 2013 showed racial differences in drug response that were, in some cases, significant enough to impact prescribing decisions.1
FDA & Other Guidance on Diversity Action Plans
US Food and Drug Administration (FDA) Diversity Action Plans are required for Phase III and other pivotal clinical studies. Here’s a deep dive into diversity regulations.
Diversity & Clinical Planning
Sponsors that make diversity in research a priority do not regard it as an afterthought; they make it part of their clinical strategy, starting with protocol design.
Diversity Challenges… and How to Overcome Them
Clinical trial diversity is filled with inherent challenges. See how study sponsors are addressing these challenges head on.
Data: Key to Unlocking Trial Diversity
Pharma faces a Catch-22 situation: Sponsors need demographic data in order to make clinical trials more diverse, but they also need to disclose the data upfront.
LGBTQIA+ Diversity in Clinical Trials
It’s up to sponsors to smooth the LGBTQIA+ patient journey for clinical trials, starting with gender-neutral protocols and making trial communication more inclusive.
Boost Diversity with Citeline Solutions & Insights
See how Citeline solutions, services, and insights can help your organization move the needle on diversity in clinical trials.
Additional Resources
We’ve curated a selection of content to help you promote diversity in clinical trials both within your organization and in the industry as a whole.